Juan de Vojníkov / Wikimedia Commons / CC BY-SA 4.0 / Archive human hair root under a microscope, 2007, resized; not a trial image
Veradermics will hold an investor call Monday morning to discuss 12-month data from a late-stage trial of its experimental extended-release oral minoxidil treatment for male pattern hair loss.
The call and live webcast are scheduled for Monday, November 9, at 8 a.m. Eastern, the company said in a November 8 company announcement. The discussion will cover topline results from Part B of Study 302, which evaluated VDPHL01 in more than 500 men with mild-to-moderate pattern hair loss.
Sunday’s announcement scheduled the presentation but did not disclose the 12-month results, safety-event counts or a regulatory action. It therefore does not establish how much hair growth was observed or whether the longer-term findings met the company’s expectations.
VDPHL01 is an investigational, non-hormonal tablet using an extended-release formulation of minoxidil. The company says its gel-matrix technology is designed to release the drug steadily over time. The formulation remains in development rather than approved for routine treatment.
Veradermics described Study 302 in the announcement as a randomized, double-blind, placebo-controlled registration-directed Phase 3 trial. Monday’s discussion concerns its 12-month Part B data, rather than a newly announced trial or an approval decision.
The company said the webcast and accompanying slides would be available through the Events page in its investor-relations website, with a replay following the call. Veradermics trades on the New York Stock Exchange under the symbol MANE.
JBizNews Desk | New Haven, Connecticut
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
